RU-47,213

RU-47,213
[[File:|frameless|220px|alt=|Chemical structure of RU-47,213]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

RU-47,213 is a synthetic compound that has been studied for its potential pharmacological effects. It is classified as a Selective Estrogen Receptor Modulator (SERM), which means it can act on the estrogen receptor with varying effects depending on the tissue type. This compound has been of interest in the field of endocrinology and oncology due to its potential applications in treating conditions such as breast cancer and osteoporosis.

Chemical Structure and Properties

RU-47,213 is a non-steroidal compound with a complex chemical structure that allows it to bind selectively to estrogen receptors. The molecular formula of RU-47,213 is C_xH_yN_zO_w, and it has a molecular weight of approximately XYZ g/mol. The compound is characterized by its ability to exhibit both agonistic and antagonistic properties depending on the target tissue.

Mechanism of Action

As a SERM, RU-47,213 binds to estrogen receptors, which are nuclear hormone receptors that regulate gene expression. In some tissues, such as bone, RU-47,213 acts as an estrogen agonist, promoting bone density and reducing the risk of fractures. In other tissues, such as breast tissue, it acts as an antagonist, inhibiting the proliferation of estrogen-dependent cancer cells. This dual action makes it a promising candidate for therapeutic use in hormone-related conditions.

Clinical Applications

Breast Cancer

RU-47,213 has been investigated for its potential use in the treatment of estrogen receptor-positive breast cancer. By acting as an antagonist in breast tissue, it may help to slow or stop the growth of cancer cells that rely on estrogen for proliferation.

Osteoporosis

In the context of osteoporosis, RU-47,213's agonistic effects on bone tissue can help to maintain or increase bone density, thereby reducing the risk of fractures in postmenopausal women.

Research and Development

Research on RU-47,213 is ongoing, with studies focusing on its efficacy, safety profile, and potential side effects. Clinical trials are necessary to fully understand its therapeutic potential and to determine the optimal dosing regimen.

Side Effects and Safety

As with other SERMs, RU-47,213 may have side effects that include hot flashes, leg cramps, and an increased risk of thromboembolic events. Long-term safety data are still being collected to assess the risk-benefit profile of this compound.

Also see

• Selective Estrogen Receptor Modulator
• Breast Cancer Treatment
• Osteoporosis
• Endocrinology
• Pharmacology

This article is a stub related to pharmacology. You can help WikiMD by expanding it!